{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:17:47Z","timestamp":1777958267903,"version":"3.51.4"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Background<\/jats:title>\n Appendiceal adenocarcinoma (AA) is a rare gastrointestinal cancer that frequently presents with peritoneal metastases; the standard of care for resectable peritoneal metastases from AA limited to the peritoneum is cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Three serum tumor markers (TMs)\u2014carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA125)\u2014may play a role in preoperative and postoperative risk estimation and decision-making in patients undergoing CRS-HIPEC.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of preoperative and postoperative serum TM levels with outcomes in patients with AA or goblet cell adenocarcinoma (GCA) undergoing CRS-HIPEC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study was conducted in a single quaternary referral cancer center. Software was used to query the MD Anderson internal patient database of patients with AA or GCA to identify a cohort receiving CRS with or without HIPEC between March 2016 and August 2024, with median postoperative follow-up of 35.6 months (range, 1.4-100.5 months). Data were analyzed from June 2024 to March 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Preoperative and postoperative levels of CEA, CA19-9, and CA125.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Association of preoperative and postoperative serum TM levels with tumor burden and likelihood of complete CRS, disease-free survival (DFS), and overall survival (OS).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 421 CRSs were included in the study, 376 (89.3%) of which were performed in patients with AA (229 [60.9%] in females; median age at surgery, 56 [IQR, 47-64] years; 290 [77.1%] were complete CRS). In AA, greater vs lesser preoperative tumor burden was associated with increased median serum TM levels (CEA: 9.5 [IQR, 3.7-42.3] ng\/mL vs 3.0 [IQR, 2.1-5.9] ng\/mL; CA19-9: 31.1 [IQR, 10.0-102.3] U\/mL vs 15.0 [IQR, 6.1-25.5] U\/mL; CA125: 28.7 [IQR, 13.9-58.5] U\/mL vs 11.5 [IQR, 8.0-17.3] U\/mL; all\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and after CRS vs before, percentages of patients with TM elevation were significantly lower (CEA: 77 of 223 [34.5%] vs 222 of 340 [65.3%]; CA19-9: 45 of 194 [23.2%] vs 117 of 324 [36.1%]; CA125: 13 of 203 [6.4%] vs 98 of 325 [30.2%]; all\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). However, complete vs incomplete CRS was associated with normalized TM levels in a greater percentage of patients (55 of 90 [61.1%] vs 7 of 52 [13.5%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Elevated vs normal preoperative TM levels were associated with increased rate of incomplete CRS (30 of 193 [15.5%] vs 1 of 95 [1.1%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and shorter DFS (hazard ratio [HR], 2.30; 95% CI, 1.46-3.64;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) but not shorter OS (HR, 1.36; 95% CI, 0.71-2.60;\n P<\/jats:italic>\n \u2009=\u2009.36). Postoperative TM elevation was associated with shorter DFS (HR, 3.73; 95% CI, 2.33-5.95;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and OS (HR, 4.10; 95% CI, 2.02-8.31;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) in univariate analyses and also in multivariate analyses (HR, 3.34; 95% CI, 1.44-7.75;\n P<\/jats:italic>\n \u2009=\u2009.005), whereas postoperative normalization of all TMs was associated with improved DFS (HR, 3.54; 95% CI, 2.01-6.23;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and OS (HR, 6.00; 95% CI, 2.06-17.46;\n P<\/jats:italic>\n \u2009=\u2009.001) in univariate analyses and also in multivariate analyses (HR, 4.21; 95% CI, 1.33-13.35;\n P<\/jats:italic>\n \u2009=\u2009.02).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of CRS in patients with AA, elevated serum TM levels were associated with worse outcomes, suggesting that patients with postoperative TM elevation after complete CRS may represent a cohort with residual tumor that requires more cautious surveillance and that both preoperative and postoperative levels of CEA, CA19-9, and CA125 should be assessed in clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.10569","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:00:18Z","timestamp":1777906818000},"page":"e2610569","source":"Crossref","is-referenced-by-count":1,"title":["Appendiceal Adenocarcinoma Cytoreduction Outcomes and Perioperative Serum Tumor Marker Levels"],"prefix":"10.1001","volume":"9","author":[{"given":"Vinay K.","family":"Pattalachinti","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"The Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health San Antonio, San Antonio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashlee","family":"Seldomridge","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor A.","family":"Fallon","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn","family":"McCullough","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betul Beyza","family":"Gunes","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Medicine, University of San Diego, La Jolla, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Scally","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith F.","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Helmink","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"3","key":"zoi260322r1","first-page":"145","article-title":"Colorectal cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi260322r2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.soc.2018.02.007","article-title":"Peritoneal metastases from appendiceal cancer.","volume":"27","author":"Votanopoulos","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"11","key":"zoi260322r3","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/cncr.32881","article-title":"The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms.","volume":"126","author":"Group","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"zoi260322r4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi260322r5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00000658-200511000-00023","article-title":"Are there curative options to peritoneal carcinomatosis?","volume":"242","author":"Sugarbaker","year":"2005","journal-title":"Ann Surg"},{"issue":"4","key":"zoi260322r6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41568-024-00788-2","article-title":"Defining a \u2018cells to society\u2019 research framework for appendiceal tumours.","volume":"25","author":"Holowatyj","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"zoi260322r7","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi260322r8","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260322r9","first-page":"143","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future.","volume":"7","author":"Dehal","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"33","key":"zoi260322r10","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","article-title":"ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.","volume":"24","author":"Locker","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi260322r11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s10120-003-0240-9","article-title":"The usefulness of CEA and\/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.","volume":"6","author":"Takahashi","year":"2003","journal-title":"Gastric Cancer"},{"issue":"4","key":"zoi260322r12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/clinchem\/47.4.624","article-title":"Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?","volume":"47","author":"Duffy","year":"2001","journal-title":"Clin Chem"},{"issue":"1","key":"zoi260322r13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41598-020-57930-x","article-title":"CA19-9 for detecting recurrence of pancreatic cancer.","volume":"10","author":"Azizian","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"zoi260322r14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.","volume":"13","author":"Felder","year":"2014","journal-title":"Mol Cancer"},{"issue":"9","key":"zoi260322r15","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3390\/jcm14093189","article-title":"Carcinoembryonic antigen (CEA): origin, role in oncology, and concentrations in serum and peritoneal fluid.","volume":"14","author":"Niedzielska","year":"2025","journal-title":"J Clin Med"},{"issue":"12","key":"zoi260322r16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","article-title":"Carbohydrate antigen 19-9\u2013tumor marker: past, present, and future.","volume":"12","author":"Lee","year":"2020","journal-title":"World J Gastrointest Surg"},{"issue":"12","key":"zoi260322r17","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.3390\/jcm14124152","article-title":"CA125 as a potential biomarker in non-malignant serous effusions: diagnostic and prognostic considerations.","volume":"14","author":"Balaceanu","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"zoi260322r18","first-page":"173","article-title":"Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy.","volume":"4","author":"Koh","year":"2013","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"zoi260322r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0260","article-title":"Serum tumor markers and outcomes in patients with appendiceal adenocarcinoma.","volume":"7","author":"Yousef","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi260322r20","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1007\/s11605-021-04953-y","article-title":"The utility of preoperative tumor markers in peritoneal carcinomatosis from primary appendiceal adenocarcinoma: an analysis from the US HIPEC Collaborative.","volume":"25","author":"Fackche","year":"2021","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"zoi260322r21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1245\/s10434-012-2627-5","article-title":"Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin.","volume":"20","author":"Wagner","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"zoi260322r22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12885-023-10545-7","article-title":"Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei.","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"zoi260322r23","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1245\/s10434-024-16860-y","article-title":"Patterns of preoperative tumor markers can predict resectability and prognosis of peritoneal metastases: a clustering analysis.","volume":"32","author":"Enblad","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"zoi260322r24","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1245\/s10434-007-9393-9","article-title":"Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"zoi260322r25","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00219","article-title":"Automated, high-throughput platform to generate a high-reliability, comprehensive rectal cancer database.","volume":"8","author":"Bhutiani","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"zoi260322r26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process.","volume":"40","author":"Carr","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"zoi260322r27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1245\/s10434-023-14422-2","article-title":"Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent mucinous appendiceal adenocarcinoma: a viable treatment strategy with demonstrable benefit.","volume":"31","author":"Bhutiani","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"zoi260322r28","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1245\/s10434-016-5209-0","article-title":"Intrathoracic chemoperfusion decreases recurrences in patients with full-thickness diaphragm involvement with mucinous appendiceal adenocarcinoma.","volume":"23","author":"Grotz","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi260322r29","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1245\/s10434-025-18672-0","article-title":"Clinicopathologic and molecular characteristics of high-grade appendiceal mucinous neoplasms.","volume":"33","author":"Seldomridge","year":"2026","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi260322r30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/ejso.2000.1038","article-title":"Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.","volume":"27","author":"Sugarbaker","year":"2001","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"zoi260322r31","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1245\/s10434-020-08844-5","article-title":"Defining \u201ccomplete cytoreduction\u201d after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) for the histopathologic spectrum of appendiceal carcinomatosis.","volume":"27","author":"Munoz-Zuluaga","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi260322r33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1245\/s10434-017-6310-8","article-title":"Histologic predictors of recurrence in mucinous appendiceal tumors with peritoneal dissemination after HIPEC.","volume":"25","author":"Reghunathan","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"zoi260322r34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16161","article-title":"Efficacy of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma: a randomized crossover trial.","volume":"6","author":"Shen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6446","key":"zoi260322r35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aaw3145","article-title":"The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.","volume":"364","author":"Engle","year":"2019","journal-title":"Science"},{"issue":"1","key":"zoi260322r36","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7521987","article-title":"The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches.","volume":"2017","author":"Lee","year":"2017","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"zoi260322r37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","article-title":"MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.","volume":"121","author":"Th\u00e9riault","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"30","key":"zoi260322r38","doi-asserted-by":"publisher","first-page":"50015","DOI":"10.18632\/oncotarget.18388","article-title":"The effect of CA125 on metastasis of ovarian cancer: old marker new function.","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"zoi260322r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00302","article-title":"Genomic landscape of appendiceal neoplasms.","volume":"2","author":"Ang","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"zoi260322r40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41698-025-00821-z","article-title":"BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.","volume":"9","author":"Pattalachinti","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"2 D","key":"zoi260322r41","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"zoi260322r42","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi260322r43","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO.2008.18.9159","article-title":"Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.","volume":"27","author":"Halabi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260322r44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study.","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi260322r45","doi-asserted-by":"publisher","first-page":"e1303","DOI":"10.1093\/oncolo\/oyad263","article-title":"Taxane-based chemotherapy is effective in metastatic appendiceal adenocarcinoma.","volume":"28","author":"Dansby","year":"2023","journal-title":"Oncologist"},{"key":"zoi260322r32","unstructured":"Therneau? TM. survival: Survival Analysis. Version 3.8-3. R Project for Statistical Computing; June 22, 2001. Accessed January 16, 2026. https:\/\/github.com\/therneau\/survival"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848557\/pattalachinti_2026_oi_260322_1777310753.82451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:00:21Z","timestamp":1777906821000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.10569","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}